Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03009214
Recruitment Status : Completed
First Posted : January 4, 2017
Last Update Posted : May 10, 2021
Information provided by (Responsible Party):
amcure GmbH

Brief Summary:
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.

Condition or disease Intervention/treatment Phase
Malignant Solid Tumor Drug: AMC303 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
Study Start Date : December 2016
Actual Primary Completion Date : July 28, 2020
Actual Study Completion Date : May 7, 2021

Arm Intervention/treatment
Experimental: AMC303

cohorts will receive ascending doses of AMC303 as intravenous infusion

Planned doses are:

0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg

Drug: AMC303
AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
Other Name: CD44v6 inhibitor

Primary Outcome Measures :
  1. Safety and tolerability of AMC303 [ Time Frame: 6 months ]
    Number of patients with treatment-related adverse events as assessed by CTCAE v4.0

Secondary Outcome Measures :
  1. Pharmacokinetic properties of AMC303 (Cmax) [ Time Frame: 2 days ]
    Determine maximum plasma concentration (Cmax)

  2. Pharmacokinetic properties of AMC303 (AUC) [ Time Frame: 2 days ]
    Determine systemic exposure (AUC) after intravenous infusion

  3. Pharmacokinetic properties of AMC303 (t1/2) [ Time Frame: 2 days ]
    Determine half-life of AMC303 after intravenous infusion

  4. Response rate of treatment with AMC303 in patients with metastatic solid tumors [ Time Frame: 12 months ]
    Determination of the complete response (CR) and partial response (PR) in patients treated with AMC303

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed and documented, advanced or metastatic, accessible malignant solid tumour of epithelial origin and for which no standard therapy exists or standard therapy has failed.
  2. Presence of a measurable tumour according to RECIST 1.1. criteria
  3. At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy (monoclonal antibodies) or cancer immunotherapy (immune checkpoint modulators) or 2 weeks from targeted therapy (receptor tyrosine kinase inhibitors) at time of administration of AMC303.
  4. Male or female patients, at least 18 years of age
  5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
  6. Life expectancy > 12 weeks.
  7. Adequate haematological function defined as

    • Absolute neutrophil count (ANC) > 1,500 / µL
    • Platelets > 100,000 / µL
    • Haemoglobin > 9 g /dL.
  8. Adequate renal function defined as

    • Glomerular filtration rate (GFR) ≥ 50 ml/min according to local laboratory standard or
    • Serum creatinine < 1.5 mg / dL.
  9. Adequate hepatic function defined as

    • Total bilirubin < 1.5x institutional upper limit of normal (ULN)
    • AST, ALT ≤ 3x institutional ULN or < 5x institutional ULN if known hepatic metastases
    • Alkaline phosphatase < 3x institutional ULN or < 5x institutional ULN if known hepatic metastases.
  10. Patient may have central nervous system (CNS) involvement if metastases have been treated and are stable at least 4 weeks after completion of radiation therapy and/or surgery. Stable disease is defined as absence of new neurological symptoms, absence of the need for steroid therapy and radiographic confirmation of stable disease. Radiographic confirmation of stable disease 4 weeks after completion of radiation therapy is not required unless indicated by neurological examination.
  11. All female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. For female participants and female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom) while on study and for 30 days after the last study treatment. For male participants or male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom,) while on study and for three months after the last study treatment.
  12. Provision of signed Informed Consent prior to any study related procedure being performed

Exclusion Criteria:

  1. Receipt of any other investigational agent within 28 days prior to first administration of AMC303. Investigational monoclonal antibodies must not be given within 6 weeks before treatment start with AMC303.
  2. Enrolment in another clinical study with an investigational drug
  3. Presence of residual toxicities of CTCAE Grade > 1 after prior anti-tumour therapy within 2 weeks of first treatment with AMC303 with the exception of Grade 3 alopecia and infusion site reactions
  4. Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements
  5. Anticipation of major surgical procedures within first 4 weeks of first dose
  6. Pregnancy or breast-feeding as determined by a serum pregnancy test (β-HCG) at screening prior to administration of AMC303 and willingness to father a child or to become pregnant
  7. Untreated acute infectious disease
  8. Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS) or is known to be HIV seropositive without AIDS defining disease
  9. Known chronic hepatitis B or C.
  10. History of allergic reactions attributed to compounds of similar chemical or biological composition to AMC303.
  11. Evidence of any other medical conditions that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications
  12. Previous malignant disease other than the target malignancy to be investigated within the last 5 years with the exception of basal or squamous carcinoma of the skin or cervical carcinoma in situ
  13. Legal incapacity or limited legal capacity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03009214

Layout table for location information
Jules Bordet Instiut
Brussels, Belgium, 1000
Cliniques Universitaires Saint Luc
Brussel, Belgium, 1200
Institut Català d'Oncologia, Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain, 08035
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal
Madiedo, Spain, 28050
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico de Valencia
Valencia, Spain, 46010
Sponsors and Collaborators
amcure GmbH
Layout table for investigator information
Study Chair: Klaus Dembowsky, MD PhD amcure GmbH
Additional Information:
Layout table for additonal information
Responsible Party: amcure GmbH Identifier: NCT03009214    
Other Study ID Numbers: AMC303-01
First Posted: January 4, 2017    Key Record Dates
Last Update Posted: May 10, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by amcure GmbH:
solid epithelial cancer
receptor tyrosine kinase
Additional relevant MeSH terms:
Layout table for MeSH terms